BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21356308)

  • 21. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
    Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
    Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
    Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
    Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
    Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
    Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
    J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
    Tauchi T; Nakajima A; Sashida G; Shimamoto T; Ohyashiki JH; Abe K; Yamamoto K; Ohyashiki K
    Clin Cancer Res; 2002 Nov; 8(11):3341-7. PubMed ID: 12429620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C; Krystal G; Dent P; Grant S
    Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs).
    Kalle AM; Sachchidanand S; Pallu R
    Leuk Res; 2010 Sep; 34(9):1132-8. PubMed ID: 20206383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
    Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
    Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
    Campbell LJ; Fidler C; Eagleton H; Peniket A; Kusec R; Gal S; Littlewood TJ; Wainscoat JS; Boultwood J
    Leukemia; 2006 Apr; 20(4):671-9. PubMed ID: 16498395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
    Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
    Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemic cells with increased telomerase activity exhibit resistance to imatinib.
    Yamada O; Kawauchi K; Akiyama M; Ozaki K; Motoji T; Adachi T; Aikawa E
    Leuk Lymphoma; 2008 Jun; 49(6):1168-77. PubMed ID: 18569639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
    Ota S; Musashi M; Kondo K; Toyoshima N; Toubai T; Onozawa M; Mori A; Hashino S; Tanaka J; Matsuno K; Imamura M; Asaka M
    Acta Haematol; 2006; 116(1):8-18. PubMed ID: 16809884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.
    Nam S; Scuto A; Yang F; Chen W; Park S; Yoo HS; Konig H; Bhatia R; Cheng X; Merz KH; Eisenbrand G; Jove R
    Mol Oncol; 2012 Jun; 6(3):276-83. PubMed ID: 22387217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B; Liang Z; Chen Z; Li B; Zheng L; Yang J; Zhou H; Qu L
    Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.